Clinical Trial Tests Red Seaweed Eye Drops for Dry Eye Disease
Dry eye disease affects millions of patients globally, yet the lubricant market has relied primarily on hyaluronic acid products for decades. A recent prospective study published in Clinical Ophthalmology examined an alternative treatment derived from red seaweed: iota-carrageenan eye drops. Researchers tested whether the natural polysaccharide could ease symptoms and protect the ocular surface in adults with mild-to-moderate disease.
Global prevalence of dry eye disease ranges anywhere from 5% to 50% depending on region and age group, making it one of the most common reasons patients visit eyecare practitioners, according to the Tear Film Ocular Society’s DEWS II report. Traditional treatments often face tolerability issues, offer little ability to help damaged tissue heal, and take weeks or months to achieve a therapeutic effect. Iota-carrageenan forms a gel on contact with the ocular surface, holds water locally, and thins under the shear of a blink so it does not fight the eyelid.
| Condition | Baseline Score | Post-Treatment Score | Mean Difference |
|---|---|---|---|
| Adverse Controlled Environment (ACE) | 21.89 | 10.00 | -11.89 |
| Normal Controlled Environment (NCE) | Not Reported | Not Reported | -8.07 |
| Ocular Surface Disease Index (OSDI) | Not Reported | Not Reported | -7.75 |
Single-Center Trial Measures Symptom Severity in Spain
Investigators ran a prospective, single-arm, open-label trial at a single center in Spain without a control group. Thirty adults with mild-to-moderate dry eye disease participated, defined by an Ocular Surface Disease Index score of 13 or higher. The mean age of participants was 50.6 years, with a range from 22 to 77 years, and 67% were female. Participants used one drop of preservative-free iota-carrageenan at 3.2 mg/mL in each eye, three times daily, for four weeks.
Symptoms were rated under two distinct environmental conditions at baseline and at the final visit. A normal controlled environment maintained 23°C with 50% humidity and no airflow, while an adverse controlled environment dropped humidity to 10% and added airflow for 90 minutes to provoke dryness. Two participants dropped out early and two missed the 80% compliance threshold, leaving 26 who finished per protocol. Effectiveness was analyzed across 28 participants with data at every visit.
Treatment Cuts Dry Eye Symptom Severity by 54%
After four weeks of treatment, the mean total dry eye score after exposure to the adverse environment fell from 21.89 to 10.00, representing a drop of 11.89 points and a 54% cut in symptom severity under stress. Under normal conditions, the score fell by 8.07 points. Most participants improved, with 93% recording a lower score after adverse environment exposure and 89% after normal conditions.
The Ocular Surface Disease Index score dropped by 7.75 points, clearing the minimal clinically important difference bar of 4.5 to 7.3 points for mild-to-moderate disease. On the Change in Dry Eye Symptoms Questionnaire, 75% of participants reported feeling better, one reported feeling worse, and the rest noticed no difference, with a mean improvement of 6.10 points among those who improved.
Corneal Damage and Tear Film Stability Improvements
Corneal damage measured on the Oxford scale improved after adverse environment exposure, dropping from 0.89 to 0.52 with a mean difference of 0.38. The spike in corneal damage seen at baseline after dry air and wind exposure disappeared after four weeks of treatment. At baseline, the adverse environment shortened tear break-up time by 0.83 seconds compared to the normal environment, but after treatment that gap shrank to 0.09 seconds. The drops showed no measurable effect on tear evaporation or tear production measured by the Schirmer test.
Tolerability remained high throughout the trial, with 90% of participants rating tolerability as good or very good after the very first drop, rising to 93% by week four. Twenty-one of the 30 participants reported a total of 107 adverse events, all of which were mild, transient, and confined to the eye. Eye pain was the most frequent at 33%, followed by itching and blurred vision at 27% each. The study recorded no serious adverse events, deaths, or pathologic intraocular pressure readings.
Answers Regarding the Red Seaweed Eye Drop Study
What are the primary limitations of this study on iota-carrageenan drops?
The trial was a small, single-center study with no control group, an open-label design that invites expectation bias, and a short follow-up period of only four weeks.
How frequently did participants apply the preservative-free drops?
Participants administered one drop of 3.2 mg/mL iota-carrageenan in each eye three times daily for the duration of the four-week trial.
What is the next required step before these results are considered settled?
Researchers state that a randomized controlled trial is the necessary next step to confirm these findings before broad clinical adoption.
Worth a look